Parafast

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Parafast

Parafast: Defining its Class and Active Ingredient

Property Description
Active Ingredient Acetaminophen (Paracetamol)
Form Tablet, Capsule, Solution, Suppository
Pharmacological Class Analgesic and Antipyretic
General Purpose Relief of pain and reduction of fever
Origin Synthetic Compound

Parafast is the trade name for a medicinal entity whose active ingredient is Acetaminophen, scientifically designated as Paracetamol. This synthetic compound, derived from the para-aminophenol chemical group, is classified in the pharmacological class of analgesics (pain relievers) and antipyretics (fever reducers). Acetaminophen is characterized by its central actions, which differentiate it from peripheral anti-inflammatory drugs. Parafast is generally positioned as a versatile, over-the-counter (OTC) product designed for managing common discomforts experienced by the general population.

Available Forms and General Therapeutic Purpose

As a monosegmental drug, its function is solely based on its one active component, Acetaminophen. Its core general therapeutic purpose is to provide symptomatic relief from mild-to-moderate pain and reduce elevated body temperature, making it a choice for managing headache or fever. Acetaminophen functions by changing the way the body senses pain and by cooling the body. To ensure broad access and utility, the active ingredient is formulated into several high-level dosage forms, including conventional tablets and capsules for oral intake, oral suspensions, and suppositories for rectal administration. Furthermore, a sterile intravenous (IV) solution exists, which is administered in controlled clinical settings for parenteral delivery.

Regulatory References

  1. Acetaminophen: MedlinePlus Drug Information

What side effects are possible with Parafast?

Possible side effects and safety information

The official safety profile for the active ingredient in Parafast, Acetaminophen/Paracetamol, is established by government regulatory authorities and primarily focuses on the potential for rare but serious adverse reactions, especially when used outside recommended limits.

Documented Adverse Reaction Categories

Adverse reactions are classified according to frequency in regulatory documents, with most effects being categorized as Rare or Very Rare.

Classification Examples of Effects Documented in Labeling
Rare Hepatic dysfunction, Hypersensitivity reactions, Agranulocytosis, Thrombocytopenia
Very Rare Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
Frequency Not Known Anaphylactic shock, Angioedema

Adverse events are generally grouped by System-Organ Class (SOC) categories, including Hepatobiliary disorders (liver), Immune system disorders, Blood and lymphatic system disorders, and Skin and subcutaneous tissue disorders.

Serious Safety Concerns

The most significant safety concern explicitly stated in regulatory labeling is the risk of Acute Liver Failure, which has been associated with use exceeding the maximum daily dose. Patients are formally advised not to use other products containing acetaminophen concurrently to avoid accidental overdose.

Population-Specific Safety Statements

Official labels include specific restrictions. The medicine is contraindicated in patients with pre-existing severe hepatic insufficiency or active liver disease due to the elevated risk of hepatotoxicity. Caution is also noted for use in patients with severe renal impairment.

Overdose and Emergency Response

Overdose Scope

The primary toxic risk of Parafast overdose is acute liver failure (hepatotoxicity), which may result in the need for liver transplant or death. Initial documented manifestations often include nausea, vomiting, abdominal pain, and pallor; however, these signs may be minimal or absent during the first 24 hours, preceding evidence of severe hepatic injury. The drug’s toxicity primarily affects the hepatic system and, rarely, can involve the dermatological system with serious skin reactions. Individuals with underlying liver disease or a history of chronic alcohol ingestion are noted in regulatory labeling as having an increased risk of severe outcomes.

Emergency Actions and Monitoring

Immediate medical attention and contacting a Poison Control Center are officially required upon suspected overdose, even if the patient feels well, due to the critical, time-sensitive nature of the toxicity. The management protocol mandates the administration of the specific antidote, N-acetylcysteine (NAC), which is essential to prevent or lessen hepatic injury. Continuous hospital observation includes serial laboratory monitoring of hepatic transaminases and the use of the Rumack-Matthew nomogram to guide antidote treatment. This required intervention framework is based on the single goal of mitigating potentially fatal hepatic injury.

Therapeutic Uses of Parafast

What Parafast Treats: Main Uses and Benefits

Parafast (Acetaminophen/Paracetamol) is an active agent used across multiple therapeutic domains to provide symptomatic relief when physical discomfort or elevated temperature create noticeable physiological strain. The medication belongs to a class of analgesics and antipyretics used to help relieve mild-to-moderate pain and reduce fever.

The primary role of the medication is applied in addressing acute and episodic pain manifestations, including common forms such as headache, muscular aches, minor joint pain, and specific discomforts like dental pain and menstrual cramps. Its antipyretic application addresses symptoms related to systemic imbalance, particularly elevated body temperature, which is often associated with seasonal viral illnesses or post-immunization discomfort.

“The benefit of the analgesic use contributes to easing the overall symptom load, helping patients cope more steadily with difficult manifestations.”

This therapeutic focus provides supportive relief in scenarios where short-term symptomatic assistance is needed. This focus contributes to easing the overall symptom load, which assists with maintaining functional stability and supports general well-being during acute episodes.


Quick Fact: Supportive Management for Acute Pain and Fever

Parafast is commonly used to help manage two primary symptom axes: pain (analgesia) and fever (antipyresis). It is applied across conditions presenting with acute episodes, relevant when patients require supportive symptom management for manifestations like headaches, body aches, and pyrexia.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Population Eligibility for Parafast

Official government regulatory documents define specific eligibility criteria for Parafast (Acetaminophen/Paracetamol) use, establishing who can and who must not use the medicine.

Regulatory Eligibility Status

Status Population or Condition
Contraindicated Patients with known hypersensitivity to the active substance or excipients, or those with severe active liver disease or severe hepatic impairment.
Established Use Adults, adolescents, and children ge 2 years of age. Use in older adults is also established, with no overall differences in safety documented.
Conditional Use Patients with severe renal impairment (creatinine clearance le 30 mL/ min), mild to moderate hepatic insufficiency, or chronic conditions leading to glutathione depletion (e.g., chronic alcoholism or chronic malnutrition).

Life Stage and Age Constraints

Use is established across all major age groups. However, effectiveness for certain formulations is not established in pediatric patients younger than two years. During pregnancy, use is permitted if clinically needed, but must be restricted to the lowest effective dose for the shortest duration. The medicine may be used while breastfeeding, as no undesirable effects on the nursing infant have been reported at therapeutic doses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Parafast is structured around pharmacokinetic and pharmacodynamic relationships documented in government sources.

Category Summary of Official Regulatory Documentation
Interacting Substances Anticoagulants (e.g., Warfarin), Gastric Motility Enhancers (Metoclopramide), Enzyme Inducers (Phenytoin, Rifampicin), Bile Acid Sequestrants (Cholestyramine), and the substance Alcohol.
Interaction Basis Interactions are officially classified as Pharmacokinetic (altering absorption/clearance), Pharmacodynamic (enhanced effects), or Metabolic (enzyme induction). Probenecid, for example, is noted to reduce Parafast clearance, increasing exposure.
Restrictions & Timing The risk of bleeding and elevated INR with Warfarin is officially noted during prolonged, regular Parafast use. Administration constraints require Parafast to be taken at least one hour before or four hours after Cholestyramine to prevent reduced absorption.
Population Notes The hazard of interaction leading to hepatotoxicity is officially greater in patients with chronic alcohol abuse or existing hepatic impairment.

Official interaction statements (high-level):

  • Regular daily co-administration with Warfarin enhances the anticoagulant effect, officially increasing the potential for bleeding.
  • Metoclopramide and Domperidone accelerate Parafast absorption; Cholestyramine significantly reduces it.
  • Co-administration with Alcohol and enzyme-inducing medicines like Phenytoin increases the risk factor for hepatotoxicity.

Connection to the overall interaction profile: The regulatory profile establishes constraints based primarily on metabolic risk associated with enzyme induction and pharmacokinetic modifications that alter the absorption and clearance rates. This formal framework defines the necessary precautions for co-administration across various classes of medicines and non-medicinal substances.

Mechanism of Action

Parafast is an antagonist of the A1 receptor, a G i-coupled protein receptor

. Its primary activity is localized within the central nervous system ( CNS). The binding of Parafast to the A1 receptor prevents the receptor's activation, which directly inhibits adenylyl cyclase activity. This intracellular inhibition reduces the generation of the second messenger cyclic AMP ( cAMP) in target neurons. The resulting decrease in the cAMP-dependent signaling cascade alters downstream enzyme phosphorylation. This molecular process acts to stabilize the excitotoxic cascade within the neuronal microenvironment. Furthermore, the overall intracellular modulation modifies the function and permeability of Ca^2+-gated ion channels embedded in the cell membrane, altering transmembrane ion flux and subsequent synaptic neurotransmission.

Dosage and Administration Information

How to Use Parafast: Official Administration Guidelines

Proper use of Parafast (Acetaminophen/Paracetamol) involves adherence to specific parameters regarding approved routes, dosing limits, frequency, and duration of use.


Official Dosing and Administration

Feature Labeled Instruction
Approved Routes Oral (tablet, capsule, liquid), Rectal (suppository), and Intravenous (IV solution).
Standard Adult Dose 325 mg to 1000 mg for immediate-release forms; 1300 mg for extended-release forms.
Maximum Daily Limit The total dose from all sources (oral, rectal, IV) must not exceed 4000 mg in a 24-hour period.
Dosing Frequency Immediate-release forms require a minimum interval of 4 to 6 hours between doses; extended-release forms are typically every 8 hours.

Procedural and Population-Specific Rules

Administration conditions and adjustments are specified for different patient populations:

  • Duration Constraint: For self-medication, use is generally limited to 10 days for pain or 3 days for fever unless directed otherwise by a healthcare professional.
  • Administration: Oral forms may be taken with or without food. Liquid suspensions must be shaken well, and the dose must be measured with the device provided by the manufacturer. Extended-release tablets must be swallowed whole.
  • Pediatric Dosing: Dosing is typically weight-based, generally 10-15 mg/kg per dose for children.
  • Organ Impairment: Patients with hepatic or severe renal impairment require dose reduction or extension of the dosing interval (e.g., to every 6 or 8 hours).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Parafast

The research base for Parafast (Acetaminophen/Paracetamol) consists primarily of officially reported studies, including Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. This body of evidence is designed to explore patterns related to symptoms, the types of outcomes measured, and the areas where scientific certainty remains low.


Research Exploring Acute Pain Relief

Research exploring short-term symptom changes in acute discomfort has extensively utilized short-term RCTs and meta-analyses. Researchers examined the difference in outcomes related to physical discomfort between participants receiving the active agent and those receiving an inactive substance in models such as post-operative pain and acute headaches. Measured outcomes included scales used to examine measured differences in pain scores and the time required for differences in discomfort levels to be observed.


Research Exploring Fever Reduction

The research foundation primarily consists of short-term RCTs and systematic reviews across different age groups. The agent was studied in conditions associated with acute or disruptive episodes of fever. Research examined temporary physiological imbalance, specifically focusing on the effect on elevated body temperature, which is an outcome related to systemic or functional imbalance. Comparative evidence was observed in some studies that described the measured outcomes when comparing the agent to other antipyretic options.


Gaps and Uncertainties in the Research Landscape

While the evidence for short-term acute use is extensive, several areas of uncertainty exist. Long-term effects are not fully established regarding the continuous administration of the agent for more than a few days. Research Exploring Chronic Pain Contexts describes that measured differences in outcomes related to physical discomfort were often found to be small. Furthermore, large-scale observational studies concerning use by pregnant women examined the statistical association between maternal exposure and certain neurodevelopmental outcomes in the child; however, this type of research cannot establish causation, and certainty remains low due to confounding factors.

Key Studies & References Acetaminophen Drug Information (Paracetamol) - General Overview and Indications

Frequently Asked Questions (FAQ)

Common questions about Parafast (FAQ)

Q: How quickly does Parafast start working after you take it?

A: According to official product information, relief from pain typically begins within 30 minutes for immediate-release oral forms. The effect usually reaches its peak effectiveness between one and two hours after the dose is taken. The specialized intravenous (IV) solution used in clinical settings has a quicker onset, often within 5 to 10 minutes.

Q: How long do the pain-relieving effects of Parafast typically last?

A: Regulatory documents indicate that the pain-relieving and fever-reducing effects of the standard immediate-release formulations generally last for about four to six hours. This duration aligns with the recommended interval between administrations noted on the product label.

Q: Can Parafast cause stomach upset like some other pain relievers?

A: While not a primary side effect like with some other types of pain relievers, gastrointestinal (GI) upset, such as mild nausea or vomiting, can sometimes occur. Unlike certain anti-inflammatory medications, the regulatory safety profile does not highlight GI bleeding or ulceration as a primary risk when the medicine is used at the recommended therapeutic doses.

Q: Can I take Parafast if I have an existing food allergy?

A: Official allergy warnings state that use is restricted if there is a known history of an allergic reaction to the active ingredient, acetaminophen, or to any of the specific inactive ingredients used in the formulation. If there are concerns about ingredients or previous allergic reactions, it is important to consult a healthcare professional.

Q: Is it normal to feel a little dizzy after taking Parafast?

A: Official regulatory safety data categorizes most side effects as rare or very rare. While the active ingredient works in the central nervous system (CNS), dizziness is not commonly reported or specifically listed as a frequent adverse event in the regulatory safety profile for the single-ingredient product when used correctly.

Q: Can Parafast be taken while trying to conceive a child?

A: No specific warnings against use while trying to conceive are typically issued in regulatory documents. Official guidance permits use during pregnancy if there is a clinical need, provided it is used at the lowest effective dose for the shortest duration necessary, as noted in the product labeling.

Q: What are the chances of becoming dependent on Parafast?

A: The active ingredient, acetaminophen, is not associated with psychological or physical dependence or addiction when used alone and as directed on the label. The risk of dependence is only noted as a concern when this ingredient is formulated in combination with opioid pain relievers.

Q: Can I use Parafast for toothache pain before seeing a dentist?

A: Official indications state that the product is approved for the temporary relief of various minor aches and pains, which includes pain caused by a toothache. However, official warnings note that professional attention is required if the pain worsens or lasts longer than the duration specified on the product label.

Q: What is the purpose of the inactive ingredients in Parafast tablets?

A: Inactive ingredients, which are listed on the official label, do not provide any therapeutic benefit. Their purpose is technical, helping to form the tablet, ensuring it dissolves properly in the body, providing color or flavor, or acting as a stabilizer for the formulation.

Q: Does Parafast work to reduce inflammation?

A: The active ingredient is primarily classified by regulatory authorities as an analgesic (pain reliever) and antipyretic (fever reducer). While its exact mechanism is complex, its anti-inflammatory effects in the body are generally considered weak or not clinically significant when compared to other types of pain medication like NSAIDs.

Q: Is Parafast safe for teenagers to take?

A: Yes, official regulatory guidelines state that the use of this medication is established across all major age groups, including adolescents (teenagers). Standard adult dosing guidelines typically apply to individuals 12 years of age and older. It is important to follow the package directions for specific age-appropriate limits.

Q: What are the signs of Parafast not working for my fever?

A: Official 'Stop Use' warnings indicate that a healthcare professional should be consulted if the fever worsens or persists for more than three days, as this may be a sign of a serious underlying condition requiring medical evaluation.

Q: Can Parafast be used for a regular headache?

A: Yes, regulatory documents explicitly list the temporary relief of minor aches and pains, including headache, as an approved and intended use for this product.

Q: Does Parafast help with muscle soreness after exercise?

A: Yes, official indications state that the product is intended for the relief of minor aches and pains, which includes muscular aches.

Q: Is it true that Parafast only treats symptoms and not the cause of the pain?

A: Yes, according to the pharmacological classification, the core function of the active ingredient is to provide symptomatic relief from pain and fever. The medication does not treat or cure the underlying condition or illness causing the discomfort.

Q: What type of pain does Parafast help with most effectively, according to studies?

A: Official regulatory documents and research summaries indicate the product is most effective for the temporary relief of mild-to-moderate pain. It is commonly indicated for types of discomfort such as headache, backache, and toothache.

How should Parafast be stored and disposed of?

The storage and disposal of Parafast (Acetaminophen/Paracetamol) must adhere strictly to official regulatory requirements to ensure product quality and public safety.

Storage Requirement Official Regulatory Instruction
Temperature Store at controlled room temperature (20 C to 25 C or 68 F to 77 F); avoid excessive heat and do not freeze.
Protection Keep in the original container, tightly closed, and store in a dry place protected from moisture.
Child Safety Keep out of the sight and reach of children to prevent accidental exposure.
Disposal Dispose of unused medicine via an authorized drug take-back program. If unavailable, mix the medicine with an undesirable substance (like coffee grounds or kitty litter), place it in a sealed bag, and discard it in the household trash, ensuring all personal information is scratched from the label. The product should not be flushed down the toilet unless the official labeling directs otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Parafast found in:

A-Z Index: